To date, the limited research on SPOCK1 in breast cancer has shown that it enhances cell proliferation, cell cycle progression, and EMT through activation of the AKT/mTOR signaling pathway, and that these effects can be reversed by either inhibiting AKT/mTOR signaling or depleting SIX1 (12). Here, MTOR is linked to breast carcinoma.